NL-OMON26780已完成不适用
A randomized phase III study of i.v. zoledronate (administered for 12 versus 36 months) as an adjunct to standard therapies in the treatment of multiple myeloma. A phase III study.
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl0 个研究点目标入组 407 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 407
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients with a confirmed diagnosis of multiple myeloma stage II or III according to the Salmon & Durie criteria;
- •2. Patients with at least one osteolytic bone lesion on conventional radiographs (plain film);
排除标准
- •1. Treatment with bisphosphonates at any time during the 12 months prior to registration. Exception: patients may have received up to 3 doses of a bisphosphonate for hypercalcaemia provided this has been administered > 14 days prior to registration;
- •2. Corrected (adjusted for serum albumin) serum calcium < 2.00 mmol/l or > 2.80 mmol/l;
研究者
相似试验
招募中
2 期
Randomized phase II study of zoledronate administration schedule comparing every 4 weeks versus every 8 weeks for metastatic lung cancer with bone metastasisPrimary lung cancerJPRN-UMIN000009369Institute of Biomedical Research and Innovation210
已完成
3 期
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation PeriodPaget's Disease of BoneNCT00051636Novartis Pharmaceuticals172
已完成
3 期
Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving LetrozoleBreast CancerNCT00376740Soroka University Medical Center90
进行中（未招募）
不适用
An open label pilot study of Zoledronate (Aclasta 5mg iv) in the treatment of Ankylosing Spondylitis - Zolinas07Ankylosing SpondylitisMedDRA version: 9.1Level: LLTClassification code 10002556Term: Ankylosing spondylitisEUCTR2007-000087-25-GBCambridge University Hospitals NHS Foundation Trust
已完成
3 期
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate CancerProstate CancerNCT00242567Novartis Pharmaceuticals522